中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2014年
7期
698-700
,共3页
李琴%刘丽军%信栓力%常超%刘东燕%崔雪霞%张书丽%李雅琪%代艳君%张芙娴
李琴%劉麗軍%信栓力%常超%劉東燕%崔雪霞%張書麗%李雅琪%代豔君%張芙嫻
리금%류려군%신전력%상초%류동연%최설하%장서려%리아기%대염군%장부한
冠心病%冠状动脉介入术%单核细胞趋化因子 1%基质金属蛋白酶 9
冠心病%冠狀動脈介入術%單覈細胞趨化因子 1%基質金屬蛋白酶 9
관심병%관상동맥개입술%단핵세포추화인자 1%기질금속단백매 9
Coronary artery disease%Percutaneous coronary interventional%Monocyte chemotactic factor-1 protein%Matrix metalloproteinase-9
目的：探讨冠心病患者行冠状动脉介入（PCI）治疗前后血浆单核细胞趋化因子1（MCP-1）及基质金属蛋白酶9（MMP-9）的改变。方法连续入选经冠状动脉造影证实单支病变的冠心病患者50例（PCI 组），冠状动脉正常者30例（对照组），检测对照组造影前后和 PCI 组介入前后血浆 MCP-1和MMP-1，比较两组间的差异。结果（1）PCI 组患者介入后血浆 MCP-1为（19.87±5.31）ng/ L，介入术前为（15.71±5.23）ng/ L，差异有统计学意义（t =3.95，P ＜0.01）；对照组冠状动脉造影术后 MCP-1为（13.78±5.58）ng/ L，术前为（12.42±5.39）ng/ L，差异无统计学意义（P =0.34）。（2）PCI 组患者介入术后血浆 MMP-9为（22.69±5.97）mg/ L，术前为（19.52±5.72）mg/ L，差异有统计学意义（t =2.71，P＜0.01）；对照组冠状动脉造影术后 MMP-9为（17.53±5.51）mg/ L，造影术前为（16.69±5.42）mg/ L，差异无统计学意义（P =0.55）。结论 PCI 促进冠心病患者血浆 MCP-1及 MMP-1水平的升高，是否为介入治疗术后支架内再狭窄的重要机制之一尚待进一步考证。
目的：探討冠心病患者行冠狀動脈介入（PCI）治療前後血漿單覈細胞趨化因子1（MCP-1）及基質金屬蛋白酶9（MMP-9）的改變。方法連續入選經冠狀動脈造影證實單支病變的冠心病患者50例（PCI 組），冠狀動脈正常者30例（對照組），檢測對照組造影前後和 PCI 組介入前後血漿 MCP-1和MMP-1，比較兩組間的差異。結果（1）PCI 組患者介入後血漿 MCP-1為（19.87±5.31）ng/ L，介入術前為（15.71±5.23）ng/ L，差異有統計學意義（t =3.95，P ＜0.01）；對照組冠狀動脈造影術後 MCP-1為（13.78±5.58）ng/ L，術前為（12.42±5.39）ng/ L，差異無統計學意義（P =0.34）。（2）PCI 組患者介入術後血漿 MMP-9為（22.69±5.97）mg/ L，術前為（19.52±5.72）mg/ L，差異有統計學意義（t =2.71，P＜0.01）；對照組冠狀動脈造影術後 MMP-9為（17.53±5.51）mg/ L，造影術前為（16.69±5.42）mg/ L，差異無統計學意義（P =0.55）。結論 PCI 促進冠心病患者血漿 MCP-1及 MMP-1水平的升高，是否為介入治療術後支架內再狹窄的重要機製之一尚待進一步攷證。
목적：탐토관심병환자행관상동맥개입（PCI）치료전후혈장단핵세포추화인자1（MCP-1）급기질금속단백매9（MMP-9）적개변。방법련속입선경관상동맥조영증실단지병변적관심병환자50례（PCI 조），관상동맥정상자30례（대조조），검측대조조조영전후화 PCI 조개입전후혈장 MCP-1화MMP-1，비교량조간적차이。결과（1）PCI 조환자개입후혈장 MCP-1위（19.87±5.31）ng/ L，개입술전위（15.71±5.23）ng/ L，차이유통계학의의（t =3.95，P ＜0.01）；대조조관상동맥조영술후 MCP-1위（13.78±5.58）ng/ L，술전위（12.42±5.39）ng/ L，차이무통계학의의（P =0.34）。（2）PCI 조환자개입술후혈장 MMP-9위（22.69±5.97）mg/ L，술전위（19.52±5.72）mg/ L，차이유통계학의의（t =2.71，P＜0.01）；대조조관상동맥조영술후 MMP-9위（17.53±5.51）mg/ L，조영술전위（16.69±5.42）mg/ L，차이무통계학의의（P =0.55）。결론 PCI 촉진관심병환자혈장 MCP-1급 MMP-1수평적승고，시부위개입치료술후지가내재협착적중요궤제지일상대진일보고증。
Objective To explore the change of monocyte chemotactic factor-1 protein(MCP-1)and matrix metalloproteinase-9( MMP-9)of patients with coronary artery disease( CAD)following percutaneous coronary interventional( PCI). Methods Fifty patients underwent PCI procedures for CAD compromising a single coronary artery were selected as PCI group and 30 healthy individuals with normal findings by coronary angiography were selected as the control group. Plasma MCP-1 and MMP-9 were measured in all the subjects. Results The plasma MCP-1 level of patients with CAD after PCI was(19. 87 ± 5. 31)ng/ L,higher than that before operation((15. 71 ± 5. 23)ng/ L,t = 3. 95,P < 0. 01). Whereas in the control group,the MCP-1 level after coronary angiography was(13. 78 ± 5. 58)ng/ L,which was as same as that before operation (12. 42 ± 5. 39 ng/ L,P = 0. 34). Plasma MMP-9 level in the CAD patients after PCI procedures was(22. 69 ± 5. 97)mg/ L,higher than that before operation((19. 52 ± 5. 72)mg/ L,t = 2. 71,P < 0. 01). There was no significant difference in term of plasma MMP-9 level in control group befor and after operation((17. 53 ± 5. 51) mg/ L vs.(16. 69 ± 5. 42)mg/ L,P = 0. 55). Conclusion Plasma MCP-1 and MMP-9 increase in CAD patients following PCI procedures. But their roles in the vascular restenosis following the procedures need further investigation.
